CGRP Receptor Antagonism with Rimegepant as an Acute Intervention for repeated idiopathic sudden sensorineural hearing loss : A Case Report
This case report demonstrates that a single daily dose of the CGRP receptor antagonist rimegepant effectively restored hearing and resolved symptoms in a 27-year-old woman with recurrent idiopathic sudden sensorineural hearing loss and a history of migraine, supporting the concept of cochlear migraine and the potential of CGRP-targeted therapy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine your inner ear is a tiny, delicate orchestra playing a perfect symphony. For six years, a 27-year-old woman's left ear orchestra kept suddenly stopping mid-song. She would feel like her ear was stuffed with cotton (aural fullness), hear a low buzzing (tinnitus), and lose her hearing, but strangely, she never felt dizzy. Doctors had tried everything: steroids, diuretics, and herbal extracts. It was like trying to fix a broken radio by hitting it with a hammer—sometimes it worked for a minute, then stopped again.
The big mystery was: Why was the music stopping?
The doctors noticed something crucial. This woman didn't just have ear trouble; she had a decade-long history of migraines (those intense, throbbing headaches). Her ear attacks happened right after the same things that triggered her headaches: lack of sleep, stress, or her period. This led the team to a new idea: maybe her ear wasn't sick on its own, but was actually a victim of a "Cochlear Migraine." Think of it like a cousin to the famous "Vestibular Migraine" (which causes dizziness), but instead of attacking the balance center, this migraine variant decided to throw a tantrum in the hearing center.
The "Smoking Gun" and the New Key
The team suspected that a tiny chemical messenger called CGRP was the troublemaker. In a migraine, CGRP acts like a fire alarm that tells blood vessels to swell and leak fluid, causing pain. The doctors thought this same alarm was going off inside her ear, flooding the delicate hearing cells with fluid and messing up the music.
To test this, they tried a new kind of key: a drug called Rimegepant. This drug is a "CGRP receptor antagonist," which is a fancy way of saying it's a shield that blocks the fire alarm from ringing.
The Result
The patient took a single 75 mg dose of Rimegepant. The result was dramatic. Within days, the "cotton" in her ear vanished, the buzzing quieted down, and her hearing came back. In fact, her hearing test on day six showed the best results she had seen in six years. It was as if the shield had successfully stopped the flood, allowing the orchestra to play again.
What This Means (and What It Doesn't)
This story suggests that for some people with recurring hearing loss and migraines, the problem isn't just an ear infection or fluid buildup in the traditional sense; it's a migraine attack happening inside the ear. The paper argues that the old way of treating this—just using steroids or diuretics—often misses the real cause.
However, the authors are careful not to shout "We solved it!" just yet. They explicitly state that this is one single case report. It's a very strong clue, like finding a perfect fingerprint at a crime scene, but it's not a full conviction. They suggest that Rimegepant may be a great targeted therapy, but they need to study many more patients to be sure. They also ruled out that this was a standard inner ear disease (like Ménière's) causing the dizziness, because the patient had no dizziness at all, even though their MRI showed some fluid swelling that usually causes it. The brain had apparently learned to ignore the swelling, but the hearing loss was still real.
So, while this isn't a magic cure for everyone, it opens a fascinating new door: sometimes, to fix the ear, you might need to treat the migraine. And for this one patient, blocking that chemical alarm worked better than anything they had tried before.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.